Cross Research SA

Via F.A. Giorgioli
6864 Arzo

Möchten Sie eine Akquiseliste erstellen?

Firmeninformationen Cross Research SA


Nature of business:
CROSS RESEARCH is licensed for Phase I studies to be carried out in healthy volunteers and special populations with the aim of assessing drug safety, kinetics and disposition; establishing kinetic-dynamic relationships; measuring drug time-course of action, to propose proper therapeutic dose regimens and fulfil the Regulatory request.
Strategic Service as the centralised clinical lab, analytical labs for drug assay and pharmaceutical labs for implementing formulation technology are co-operating with CROss Alliance on the basis of preferential contracts.

Phase 1: Safety studies
- Single ascending dose tolerability & pharmacokinetics (First in man)
- Multiple dose tolerability & pharmacokinetics
- Local tolerability & sensitisation potential
- Photo-toxicity and photo-sensitisation
- Evaluation of gastro-intestinal tolerability of drugs by gastroscopy and by measuring sugars permeability
- QTc prolongation studies
- Drug-interaction studies

Clinical pharmacokinetics
- Single / Multiple dose pharmacokinetics
- Bioavailability / Bioequivalence
- Effect of meal
- Effect of exercise
- Pharmacokinetics in elderly
- Pharmacokinetics in post-menopausal women

Phase 2: Special Studies
- Adhesiveness study for patch development including objective computerised measurements.
- Cations and anions binders effectiveness within the GI tract for drug development in nephropathy.
- Induction of ketonic bodies: a model for anti-diabetic drugs.
- Cheese-effect for MAO inhibitors screening.
- Medical device testing in pneumology.

Statutory auditors:
• Studio Fiam SA, Lugano

Allgemeine Informationen

Gründungsjahr 1997
Handelsregister-Nr. CHE-108.671.859
Rechtliche Hinweise Aktiengesellschaft
Kapital 120'000 CHF
Art des Unternehmens Hauptsitz
USt-ID.Nr. CHE-108.671.859 IVA
Fax +41 916404451

Kennzahlen Cross Research SA

Führungskräfte Cross Research SA

Infos über Führungskräfte

Signor Alessandro Assandri


Geschäftsfelder Cross Research SA

Das könnte Sie interessieren